Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Gulo who wrote (3433)	10/24/2003 7:30:49 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 23958

gulo, You could be right as they don't actually name the drug used, but I disagree with you on the issue of it not being a drug to fight inflammations. The following information might help clarify that point.. "Discovery Laboratories, Inc. (DSCO) is a specialty pharmaceutical company applying its platform technology, based on humanized lung surfactants, to develop potential novel respiratory therapies and pulmonary drug delivery products. Surfactants are substances that are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen. DSCO's humanized surfactant technology is being developed initially for critical care patients with life-threatening respiratory disorders where there are few, if any, approved therapies. These severe respiratory disorders generally are associated with a lack of functional surfactant. Surfaxin, DSCO's lead product, is the first humanized, protein B-based agent that mimics the surface-active properties of human surfactant. Surfaxin has been shown to remove inflammatory and infectious infiltrates from patients' lungs when used by its proprietary lavage (or lung wash) and replenish the vital surfactant levels in the lungs. Surfaxin has been in clinical trials for Respiratory Distress Syndrome in premature infants, for Meconium Aspiration Syndrome in full-term infants and for Acute Respiratory Distress Syndrome in adults. SurfSurfaxin is delivered in a liquid form and is injected through an endotracheal tube (a tube inserted into the infant's mouth and down the trachea) in premature infants, and as a proprietary lavage through a tube, called a bronchoscope, in full-term infants and adults. In April 2003, DSCO announced that its lung surfactant technology had been developed as an inhalable aerosol formulation with the potential to treat a range of respiratory conditions such as acute lung injury, chronic obstructive pulmonary disease and upper airway disorders such as sinusitis and sleep apnea. With this progression, Surfaxin moved to late stage, clinical trials for the treatment of Respiratory Distress Syndrome in clinical care patients. The company's lead development programs for its liquid Surfactant Replacement Therapy will be geared to treating hospital patients with severe asthma and acute lung injury. DSCO believes that its platform technology has the potential to generate products for non-critical care, ambulatory markets. The company is developing a dedicated sales and marketing capability through a collaboration with Quintiles Transnational to commercialize Surfaxin in the U.S., and has also formed an alliance with Laboratorios del Dr. Esteve to commercialize Surfaxin in Europe, Central and Latin America. DSCO may establish additional alliances to commercialize its products in other markets.